GlobeNewswire Inc | Feb 2, 2021 04:05PM EST

February 02, 2021

SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), today announcedthe closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $1.11 per share. As a result of the underwriters' exercise of the option, the aggregate gross proceeds to Adamis from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the company, was approximately $51.7million.

Raymond James & Associates, Inc. acted as the sole book-running managerfor theoffering.

The company intends to use the net proceeds from this offering for general corporate purposes, which may include, without limitation, expenditures relating to research, development and clinical trials relating to its products and product candidates, capital expenditures, manufacturing, hiring additional personnel, acquisitions of new technologies or products, the payment, repayment, refinancing, redemption or repurchase of existing or future indebtedness, obligations or capital stock, and working capital.

The securities described above were offered by the company pursuant to a shelf registration statement on Form S-3 (File No. 333-226100) previously filed with and declared effective by the Securities and Exchange Commission (the SEC) on July 18, 2018. A final prospectus supplement and the related prospectus have been filed with the SEC and are available on the SECs website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida, or by telephone at (800)248-8863, or e-mail at prospectus@raymondjames.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The companys SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma and COPD. The companys subsidiary, USCompounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the public offering and the intended use of the net proceeds from the offering and statements about future developments relating to companys product candidates. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to, the companys beliefs concerning the following statements: the intended use of proceeds from the offering described in this press release; and future developments regarding the companys products and product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the companys actual results to be materially different from these forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made and should not be relied upon as representing the companys views as of any subsequent date, and except as may be required by applicable law, we expressly disclaim any, undertake no, obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis filings from time to time with theSEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on theSEC'sweb site at http://www.sec.gov.

Contact:Mark FlatherSenior Director, Investor Relations& Corporate CommunicationsAdamis Pharmaceuticals Corporation(858) 412-7951mflather@adamispharma.com